Recently, much work has been done exemplifying metabolic and oxidative stress vulnerabilities as promising targets for triggering physiological cell death in cancers selectively 1 . Oxidative stress can be a result of over production of reactive oxygen species (ROS) and/or a decrease in antioxidant defense systems. When the redox systems are imbalanced, this can lead to damage of macromolecules that can negatively influence whole organisms 2 . Cellular ROS can be synthesized intrinsically through various organelles including but not limited to the mitochondria, endoplasmic reticulum and peroxisomes or as a result of environmental factors including UV radiation, tobacco, xenobiotics, metals and ions 3, 4 . Interest in exploiting ROS to target cancer cells selectively has risen since cancer cells often exhibit higher levels of oxidative stress 5 . Consequently, this could render cancer cells more vulnerable to exogenous sources of ROS or stimuli that promote oxidative stress 5 . The combination of agents that increase ROS and those that suppress antioxidant defenses has been shown to be an effective treatment of different blood cancers with limited effects on normal lymphocytes [6] [7] [8] . These results have led to further successful clinical trials in lung, breast, and pancreatic cancers 9 . The use of nutraceutical or derived compounds alone or in combination with chemotherapies has been used pre-clinically, clinically and anecdotally for years with encouraging results 10 . The natural compound, curcumin, isolated from the Curcuma longa plant is one molecule that has been significantly studied. Curcumin has been shown to directly or indirectly modify the activity of a variety of signaling molecules, including but not limited to transcription factors, enzymes, cell cycle regulatory proteins, cell survival proteins, and inflammatory molecules yielding various pleiotropic downstream effects 11 . Curcumin has been previously characterized to have antioxidant effects, although there have been reports of potential pro-oxidant properties [12] [13] [14] [15] . Despite the extensive and promising pre-clinical findings of curcumin, it performed very poorly in clinical trials as a mono or combinatorial therapy as a result of its poor bioavailability and stability leading to serum concentrations below its critical pharmacological concentration [16] [17] [18] . Efforts have been made to increase curcumin's bioavailability through the
at 24 hours was observed following treatment with Compound A and I, while there was punctate TMRM staining in the control and treated NHF cells at 48 hours (Fig. 4d,e) . Similar decrease in TMRM positive cells for HCT-116 and MV-4-11 cell lines was observed with limited effects seen in the normal colorectal cell line, NCM460 ( Supplementary Fig. 3 ). The destabilization of the mitochondria was further confirmed by monitoring the release of cytochrome c (Cyto C) into the cytosol following Compound A and I treatment using Western blot analysis of proteins in the mitochondria and cytosol: there was an increase in the levels of cytosolic Cyto C and a decrease in the mitochondrial fractions (Fig. 4f) .
The ratio of anti-apoptotic BCL-2 to pro-apoptotic BAX protein plays a critical role in the survival and death of the cells 26, 27 . We monitored the level of BCL-2 to BAX proteins in E6-1 cells following treatment with Compound A and I. There was a decrease in the ratio of anti-apoptotic protein BCL-2 to the pro-apoptotic BAX protein (Fig. 4g,h ) indicating a state that favors mitochondrial depolarization and subsequent execution of apoptosis.
Furthermore, to investigate the role of multiple death pathways, we utilized Jurkat cells either overexpressing BCL-2 (BCL-2 Jurkat) or lacking a functional Fas-associated protein with Death Domain (FADD; dnFADD Jurkat). Confirmation of a non-functional FADD protein can be seen by the lack of Annexin V and PI markers ( Fig. 5a ) and lack of caspase-8 cleavage ( Supplementary Fig. 5 ) compared to the normal jurkat cells following treatment with the Fas ligand (FasL) 28 . Compounds A and I maintained their ability to induce apoptosis, albeit at a lower rate compared to the normal jurkat cell line (Fig. 5a ). Interestingly, they maintained their ability to cause mitochondria destabilization in the BCL-2 Jurkat cell line ( Supplementary Fig. 4a ). Furthermore, when curcumin analogs and curcumin were added in combination with electron transport chain complexes I, II, or III inhibitors, there was no inhibition of apoptosis ( Supplementary Fig. 4b ). This indicates their activity to be independent of these complexes and the overall function of the electron transport chain. To investigate the role of caspases in activation of apoptosis by Compound A and I, the broad-spectrum caspase inhibitor, Z-VAD(oMe)-FMK was utilized. In the presence of this inhibitor, there is a partial reduction in Annexin V and PI markers at 48 hours in E6-1 and MV-4-11 cell lines ( Fig. 5b and Supplementary  Fig. 6 ). Western blot analysis indicated that there was activation of caspase-8, -9, and -3 as well as increases in Compared to Natural Curcumin. Cells were treated with various doses of curcumin, curcumin analogs, or common chemotherapeutics for 48 hours. Following treatment, WST-1 cell proliferation assay was used and the absorbance at 450 nm was measured. Y-axis is the percent mean ± SD from three independent experiments to the DMSO control and the x-axis is the concentrations used in micromolar. Results graphed using the log(inhibitor) vs response -Variable slope (four parameters) curve using GraphPrism6. double-stranded DNA breaks (as indicated by γH2AX) following treatment with Compound A and I (Fig. 5c ). However, Z-VAD(oMe)-FMK pre-treatment was able to effectively block the generation these markers. Moreover, the caspase-3 activation and presence of γH2AX were not evident in non-cancerous cells including NHF and NCM-460 following treatment with Compounds A and I for 48 or 72 hours ( Fig. 5d) , further supporting the selective nature of these analogs.
Induction of Oxidative Stress by Compound A and I Selectively in Cancerous Cells is Critical for the Induction of Cell Death.
Further investigating the mechanism of induction of apoptosis by these compounds, we observed that they induced production of ROS in different cancer cell lines as indicated by an increase in percent of cells positive for DCF relative to the control (Fig. 6a-c) . We wanted to investigate if this increase in oxidative stress is essential in the downstream effects of these compounds for the induction of apoptosis by these analogs. When pre-treated with the antioxidant NAC, there was a near complete reduction in the markers for apoptosis and mitochondria destabilization across numerous cancerous cell lines following treatment with Compound A and I (Fig. 6d-f and Supplementary Fig. 7 ). Interestingly, Compounds A and I were able to induce ROS generation appreciably in the cancer colorectal cell line, HCT-116, but not in the normal NCM460, colon epithelial cells at 6 and 24 hours (Fig. 6i,j) . Furthermore, these results were complimented by the reduction in the cleavage of caspase-3, -8, and -9 and presence of γH2AX (Fig. 6g) by NAC co-treatment.
As indicated above, the induction of apoptosis was near completely blocked as shown by the drastic decrease of apoptotic markers. However, further experiments were performed to determine if these cells rescued by NAC are fully functional in terms of cell division. Cells were treated with NAC, Compound A, or a combination of the two for 24 or 48 hours. Following the treatment, cells were washed and re-plated with an equal amount of cells in fresh media and counted at 24, 48, and 72 hours to obtain the growth kinetics (Fig. 6h) . Compound A-treated groups were stagnant or decreased in total cell number for both MDA-MB-231 and E6-1 cell lines as time progressed, while the NAC and a combination of Compound A and NAC treated groups had a similar rate of growth to the DMSO (control) group.
Previous work has shown a water-soluble formulation of Coenzyme Q 10 (Ubs-CoQ 10 ) to inhibit ROS production and protect against mitochondria-mediated apoptosis 29, 30 . Ubs-CoQ 10 was used and shown to reduce the percent of cells that underwent apoptosis by Compound A and I as indicated by the reduction in the Annexin V and PI apoptotic markers ( Supplementary Fig. 8 ) further supporting the role of oxidative stress caused by these compounds in inducing cancerous cell death.
Gene Expression Analysis of Oxidative Stress-Related Genes in Cancer and Normal Colon Cell Lines Following Treatment with Compound A. To investigate if the treatment with Compound A leads
to differential gene expression profile in cancer cells compared to normal cells, RT 2 PCR was carried out. Since an increase in ROS production was the first event observed at 6-hours following the treatment with no significant cell death, analysis was performed at this time point (Fig. 6i and Supplementary Fig. 9 ). In summary, of the 84 genes analyzed, six genes were clearly differentially expressed between cancer and non-cancerous cell types (Fig. 7a) . These genes are involved in maintaining redox homeostasis, production of reactive oxygen species, and inflammatory signaling. Five of these (AOX1, MPO, PRDX4, NCF1, and NOX5) were found to be decreased in the cancerous cells following Compound A treatment while these genes were up-regulated in the normal cell line. These observations indicate that cancer cells may respond in exact opposite way in terms of gene expression to Compound A treatment. Furthermore, following treatment with Compound A, there were over 40 genes related to radical quenching, oxidative stress response, and autophagy or inflammatory pathways, which had a statistically significant change in mRNA expression in one cell line and a non-significant change in the other (Fig. 7c) . These are important observations, which indicated that cancer and normal cells trigger differential gene expression response following Compound A treatment. Ten genes were found to have similar pattern of statistically significant changes in mRNA expression in both cell types (Fig. 7b) including a decrease in genes related to cell proliferation, migration (ALOX12 and FOXM1), ROS quenching proteins (CAT and TPO) as well as an increase in genes involved in preventing oxidative stress or cell death (MT3 and HMOX1).
Lastly, the other twenty-eight genes analyzed were found to be statistically non-significant in their change in mRNA expression and can be found in Supplementary Fig. 10 . A summary of all genes, their abbreviated function, relative-fold change, and statistical significance can be found in Tables 2-8.
Apoptotic Induction of Compound A is Enhanced by Combinatorial Treatment with
Piperlongumine, Another ROS Inducing Compound. Recently, the natural compound piperlongumine (PL) has been found to induce ROS production and apoptosis selectively against cancer cells in vitro and in vivo taking advantage of their altered redox state 31 . We wanted to investigate if adding PL in combination with Compound A will have enhanced/synergistic effects in terms of inducing cell death in cancer cells. Indeed, PL was able to induce ROS generation in cancer cell lines alone (Fig. 8a,b) , but in combination with Compound A there was a synergism in apoptotic induction in several blood (Fig. 8c,d ) and triple-negative breast (Fig. 8e,f) cancer cell lines. More importantly, this combinatorial treatment was well tolerated in non-cancerous cells including PMBCs, NCM460, and NHF cells (Fig. 8g-i) exemplifying the selective anti-cancer activity of this combination treatment. These results were further confirmed by the absence of caspase-3 activation and presence of γH2AX in the NHFs at 48 hours ( Supplementary Fig. 12 ) following the combinatorial treatment. Similar synergistic apoptotic and ROS generation effects were found in the BxPC-3 pancreatic cancer cell line ( Supplementary Fig. 11 ).
Intraperitoneal Administration of Compound A Effectively Suppresses Xenograft Growth of Human Leukemia and Triple-Negative Breast Cancer in Mice.
Having seen effective and selective induction of cell death by Compound A in a number of cancer cell lines, we wanted to evaluate if this compound and its ability to inhibit the growth of aggressive, triple-negative breast cancer and leukemia xenografts in mice. Human leukemia (MV-4-11) and triple-negative breast cancer (MDA-MB-231) cells were transplanted subcutaneously in immunocompromised mice as described in materials & methods. Following tumor establishment, Compound A was administered intraperitoneally over the course of 5 weeks. Compound A was able to decrease the growth of the xenograft as determined by tumor size relative to the vehicle control (Fig. 9a,b) . Furthermore, in the MV-4-11 xenograft model, Compound A was slightly more effective at suppressing tumor growth compared to natural curcumin given at similar doses. Over the five-week studies, there was no apparent change in body weight of mice in each group compared to the control, indicating tolerance of the given compounds by the animals. Furthermore, immunohistochemical staining indicated apoptotic induction by Compound A in tumor tissues and not in vital organs and noncancerous mouse tissue (Fig. 9c) . There was an increase in cleaved caspase-3 and γH2AX as well as a reduction in positive staining for PCNA, a marker for cellular proliferation, in the Compound A treated group compared to the control group in the tumor sections. Additionally, there was a reduction in VEGF in the tumor sections and no apparent changes in PCNA or γH2AX staining in heart and kidney sections respectively for both groups ( Supplementary Fig. 14) . Thus, these findings illustrate that Compound A is effectively in reducing tumor growth in vivo and is well tolerated by the animals used in this study.
Discussion
Curcumin has been enticing for its use as a chemopreventative and chemotherapeutic compound. Previous literature has shown curcumin to be well tolerated in humans and to induce apoptosis selectively in cancerous cells with limited effects in normal cells in vitro [32] [33] [34] . However, its limited bioavailability and stability has limited its further use in a clinical application 18, 19, 35 . Herein, we present two novel MACs that are more chemically stable and effective at inducing cell death in a variety of human cancer cells including notoriously resistant, triple-negative breast and p53-negative colorectal cancer cells at doses several-fold less than natural curcumin. Furthermore, we demonstrated that their selective targeting to cancer cells is attributed to their ability to induce oxidative stress selectively in cancer cells. One of the MACs, Compound A was effective in halting the growth of human leukemia and triple-negative breast cancer xenografts in mouse models when administered intraperitoneally, indicating they are absorbed and are stable within a physiological system.
In this body of work, several MACs have been synthesized and we screened 10 analogs, Compounds A-J ( Calcium-dependent NADPH oxidase, invovled in production of superoxidee radicals, affecting cell growth and metabolism.
1.94 (0.29)** 2.90 (2.52)* Table 2 . Summary of the Relative-Fold Change in Gene Expression Utilizing RT 2 PCR. Statistical analysis was performed using One-Way ANOVA to relative-fold change of the control (1). *p < 0.05 vs control; **p < 0.01 vs control; ***p < 0.001 vs control; ****p < 0.0001 vs control. n.s. = not significant, p > 0.05 vs control. N/A = not applicable due to no amplification detected. Gene function was obtained searching the UniProt or NCBI Gene Databases.
cell lines tested (Figs 3f-j and 4c,e, Supplementary Figs 2 and 3). Interestingly, these compounds were able to be more efficacious and selective than commonly used chemotherapeutics currently in use (e.g. doxorubicin and paclitaxel). An increased efficacy in vitro could be in part due to an improved chemical stability that Compound A may possess in comparison to curcumin, which readily degrades as time progresses ( Supplementary Fig. 15 ), or a more efficient binding to the biochemical target(s) in cancerous cells.
The pleiotropic action of curcumin has been well documented to activate apoptosis independent and depend on the cleavage of caspases [36] [37] [38] [39] . Apoptotic induction can be a result of a combination of increased ROS, mitochondria membrane potential collapse, and activation of caspases. We have demonstrated that Compound A and I resulted in cancer cell mitochondrial membrane potential collapse within 24 hours of treatment but not in non-cancerous cells (Fig. 4a-e) . The mitochondrial membrane potential collapse was further evident by the release of Cyto c as seen in Fig. 4f .
The anti-apoptotic protein BCL-2 is commonly found overexpressed in many human cancers leading to the resistance to common chemo-and radio-therapies used today [40] [41] [42] . These analogs were able to decrease BCL-2 expression (Fig. 4g ) and maintained their cytotoxicity regardless of BCL-2 status in cancerous cells ( Fig. 5a and Supplementary Fig. 4 ). This mitochondrial membrane potential collapse could be caused by direct interaction of Compound A and I to the mitochondrial proteins leading to destabilization or could be indirectly induced by oxidative stress caused by Compounds A and I. When further chronological analysis of mitochondria membrane potential collapse and ROS production was carried out, we observed that there was early production of oxidative stress within 3 hours of treatment (Fig. 6a-c) , whereas mitochondrial destabilization was observed after 6 hours of treatment (data not shown). Thus, it seems likely that these compounds target redox systems in cancer cells.
Alterations in the cellular redox environment can lead to the initiation and propagation of a cancerous phenotype 43, 44 . As a result of an increased oxidative stressed environment, cancer cells for their survival, often up-regulate many antioxidant systems to cope with these stresses, relative to their normal counterparts 45 . Thus it is reasonable to suggest the use of molecules to take advantage of such elevated levels for cancer treatment. Natural flavonoids and polyphenols have traditionally been thought of as anti-oxidants, although there is literature to support their use as pro-oxidant compounds in vitro and in vivo. Such effects are believed to be a result of chelating with transition metal ions, inhibiting mitochondrial respiration, and oxidation of peroxidases or antioxidant molecules 12, 46-50 . Table 3 . Summary of the Relative-Fold Change in Gene Expression Utilizing RT 2 PCR. Statistical analysis was performed using One-Way ANOVA to relative-fold change of the control (1). *p < 0.05 vs control; **p < 0.01 vs control; ***p < 0.001 vs control; ****p < 0.0001 vs control. n.s. = not significant, p > 0.05 vs control. N/A = not applicable due to no amplification detected. Gene function was obtained searching the UniProt or NCBI Gene Databases. Immunohistochemistry analysis of sectioned tumor tissues from the MDA-MB-231 study. Each section was subjected to the specified antibody followed by a biotinylated secondary antibody. Detection was done using a DAB Peroxidase HRP Substrate Kit (brown) followed by Hematoxylin counterstaining (purple). Images were obtained using inverted bright field microscopy. Sectioning results are representative of three individual tumors. Scale bar is 50 microns. Statistical analysis using One-Way ANOVA. *p < 0.05 vs tumor volume of the control.
Traditionally, the polyphenol, curcumin has been shown to be a potent anti-inflammatory and antioxidant, but herein we observe a pro-oxidant effect of curcumin and Compounds A and I in cancer cells. If the increased production of ROS is critical for the induction of apoptosis for Compounds A and I, then antioxidants or ROS-scavengers like NAC can rescue the cancer cells. Indeed, cells co-treated with these compounds and NAC showed drastically reduced ROS generation (Fig. 6a-c) and near complete reduction of apoptotic markers (Fig. 6d-f and Supplementary Fig. 7 ) as well as caspase cleavage or γH2AX (Fig. 6g) . Furthermore, cells treated with Compound A and rescued by NAC were able to resume normal cell proliferation when plated in fresh media, whereas Compound A treated cells without NAC could not resume a similar proliferative capability (Fig. 6h) . These results indicate that ROS production caused by these compounds is the initial and critical step towards induction of apoptosis in cancer cells. More importantly, these compounds did not induce appreciable ROS production in non-cancerous cells (Fig. 6j) indicating their potential selectivity to cancer cells.
These results were complimented by gene expression analysis using RT 2 PCR that demonstrated differential gene expression following Compound A treatment in cancer cells compared to their normal counterpart ( Fig. 7 and Supplementary 10 and Tables 2-8) .
In general, it appears that Compound A was able to selectively decrease the expression of several genes in the colorectal cancer cell line responsible for the defenses against ROS including but not limited to several proteins involved in glutathione-homeostasis including peroxiredoxins, glutathione peroxidases, and glutathione S-transferases. Our results indicated that cancer cells are relatively vulnerable to induction of oxidative stress compared to normal cells. Indeed, this hypothesis has also been supported by other researchers who have shown small molecules including piperlongumine 31, 51 , erastin or RSL3 52 , and beta-phenylethyl isothiocyanate 53 to induce cell death in cancer cells by targeting redox defense systems. A serine protease inhibitor, displaying anti-trypsin activity which defends against untimely trypsin-catalyzed activation of zymogens. 
GPX4 (Glutathione peroxidase 4)
Involved in the production glutathione disulfide, playing a protective role against radiation and oxidative damage. 
PRDX2 (Peroxiredoxin 2)
Involved in redox signaling, and reducing peroxides through the thioredoxin system. Table 4 . Summary of the Relative-Fold Change in Gene Expression Utilizing RT 2 PCR. Statistical analysis was performed using One-Way ANOVA to relative-fold change of the control (1). *p < 0.05 vs control; **p < 0.01 vs control; ***p < 0.001 vs control; ****p < 0.0001 vs control. n.s. = not significant, p > 0.05 vs control. N/A = not applicable due to no amplification detected. Gene function was obtained searching the UniProt or NCBI Gene D a t a b a s es .
Scientific RepoRts | 7: 1105 | DOI:10.1038/s41598-017-01230- 4 We also observed similar expression profile for a number of genes in both cancer and normal cells following Compound A treatment. The role of these genes may not be critical in the induction of cell death. On the other hand, cancer cells are believed to have higher absolute levels of ROS and antioxidant defenses to ensure their survival. Such differences could potentially render these cells to be more sensitive to absolute changes in these systems either leading to cytostatic or cell death events 5, 9, [54] [55] [56] [57] . These results further demonstrate the use of small molecules that potentially could target redox systems differentially in cancerous cells.
Targeting oxidative stress vulnerability of cancerous cells has been shown by the natural compound, PL in vitro and in vivo 31 . It plausible that the addition of curcumin analogs to PL could have enhanced effects in killing of cancer cells as we have shown these compounds to induce apoptosis in cancer cells via increased oxidative stress. We observed a synergistic apoptotic effect with the combination of PL and Compound A in different blood and triple-negative breast cancer cell lines with very limited effects on normal cells (Fig. 8c-i, Supplementary  Fig. 12 ). Thus, we present a novel combination strategy, which both hinders the cellular oxidative stress defense mechanisms and induces ROS generation to achieve an enhanced anti-cancer response. Furthermore, we have also observed that Compound A in combination with a common cocktail of chemotherapeutics, FOLFOX (composed of Folinic acid, Fluorouracil, and Oxaliplatin) had an additive effect at inducing apoptosis and mitochondria collapse in the colorectal cancer cell line, HCT-116 ( Supplementary Fig. 15 ).
The in vivo anti-cancer efficacy of natural curcumin and previously reported analogs have been less than satisfactory in terms of inhibiting human tumor xenograft growth or with the administration of high amounts of compound [58] [59] [60] [61] [62] . Interestingly, our results showed that intraperitoneally administered Compound A was very effective in reducing the volume of both human leukemia and triple-negative cancer xenograft in mice at 5.0 and 7.5 mg/ kg respectively (Fig. 9a,b) . The fact that intraperitoneal administration was efficient in reducing subcutaneous xenograft growth suggests that Compound A is absorbed sufficiently and is stable in physiological conditions. Immunohistochemical analysis shows Compound A to increase levels of cleaved caspase-3 and decrease the levels T a b le 5. Summary of the Relative-Fold Change in Gene Expression Utilizing RT 2 PCR. Statistical analysis was performed using One-Way ANOVA to relative-fold change of the control (1). *p < 0.05 vs control; **p < 0.01 vs control; ***p < 0.001 vs control; ****p < 0.0001 vs control. n.s. = not significant, p > 0.05 vs control. N/A = not applicable due to no amplification detected. Gene function was obtained searching the UniProt or NCBI Gene Databases.
Scientific RepoRts | 7: 1105 | DOI:10.1038/s41598-017-01230-4 of the proliferation marker, PCNA compared to the control tumors (Fig. 9c) , suggesting that this treatment is able to effectively induce apoptosis and reduce cell proliferation in the tumor tissue.
Notably, administration of Compound A in mice for up to 5 weeks did not cause significant changes in weight compared to control mice, thus, indicating that Compound A is well tolerated. Immunohistochemistry further supports the tolerability of Compound A as no differences were observed between the amounts of γH2AX in the kidney tissues from control and Compound A treated animals ( Supplementary Fig. 14) . Further work will be required to evaluate whether or not Compound A has a greater bioavailability compared to natural curcumin.
In summary, the novel MAC, Compound A has great potential for further development for safe and effective treatment for human cancers. Compound A is able to exert anti-cancer effects not only in vitro but effectively in vivo when administered in the peritoneal cavity. It is well tolerated, and selective in inducing apoptosis in cancerous cells by the production of ROS. This activity and selectivity may be attributed to the differential redox states that may exist between cancerous and non-cancerous cells. A limitation of this work is the lack of direct target(s) that Compound A may be affecting, whether it is in fact a protein belonging to one of these redox defense systems or pathways upstream of them and will require future investigations to fully elucidate the compounds activity. As a whole, these results merit potential avenues of research for the use of Compound A as a mono-or combinatorial therapy by targeting redox systems in cancer cells.
Materials and Methods
Chemicals. Cells were treated with curcumin analogs, curcumin (CUR; Sigma-Aldrich Canada, Cat. Component of the SKP1-CUL1-F-box protein complex involved in ubiquitination, and subsequent proteasomal degradation of proteins involved in cell cycle regulation. Table 6 . Summary of the Relative-Fold Change in Gene Expression Utilizing RT 2 PCR. Statistical analysis was performed using One-Way ANOVA to relative-fold change of the control (1). *p < 0.05 vs control; **p < 0.01 vs control; ***p < 0.001 vs control; ****p < 0.0001 vs control. n.s. = not significant, p > 0.05 vs control. N/A = not applicable due to no amplification detected. Gene function was obtained searching the UniProt or NCBI Gene Databases.
(PQ; Sigma-Aldrich Canada, Cat. No.856177, Mississauga, ON, Canada) were prepared in double distilled water stock solutions.
Chemical Synthesis of Curcumin Analogs. All chemical reagents were obtained from Sigma-Aldrich, Fluka, and Aladdin (Beijing, China). Silica gel (GF254) for thin-layer chromatography and column chromatography (100-200 and 200-300 mesh) were obtained from Aladdin. Most of compounds were synthesized by aldol condensation between aryl aldehydes and ketones (piperid-4-one, 1-methylpiperid-4-one, pyrone or 1-(2-chlorophenyl)ethanone) (Compounds A-E, G, I and J) or an additional acylation reaction (Compounds F and H). The synthesis of these unreported compounds is briefly described as following two sections.
General procedure for synthesis of compound A-E, G and I. The piperid-4-one hydrochloride (2 mmol) and corresponding aryl (4 mmol) aldehydes were dissolved in the mixture solvent of ethanol and water (10:1) to prepare Compound B, C, G, and I, while 1-methylpiperid-4-one or pyrone (2 mmol) and corresponding aryl aldehydes (4 mmol) were dissolved in absolute ethanol as well as 1-(2-chlorophenyl)ethanone (4 mmol) and 1,4-Phthalaldehyde (2 mmol). The Compounds D containing -OH group in the benzene ring were catalyzed by HCl gas. Other compounds were catalyzed by 40%NaOH at 5-8 °C. All reactions were monitored by the silica gel TLC. At the end of the reaction, water is added into the reaction mixture to precipitate the product. The crude were purified by column chromatography using PE/EA or CH 2 Cl 2 /CH 3 OH.
Preparation of compound F and H.
A mixture of piperid-4-one hydrochloride (3 mmol) and 3,4,5-trimethoxybenzaldehyde (6 mmol) in ethanol and water (10:1) was stirred at 5-8 °C. 40% NaOH solution (0.5 mL) was added in. After being stirred overnight, the resulting mixture was poured into cold water (10 mL) to precipitate the product. The filter residue was dried in the oven at 40 °C and used for next step reaction without further purification. A solution of isobutyryl chloride or acetyl chloride (2 mmol) in dichloromethane (2 mL) was added dropwise into a mixture of dried residue (1 mmol) and triethylamine (0.25 mL) in dichloromethane (8 mL) under the condition of ice-water bath (5-8 °C). After being stirred overnight at room temperature, the solvent was Table 7 . Summary of the Relative-Fold Change in Gene Expression Utilizing RT 2 PCR. Statistical analysis was performed using One-Way ANOVA to relative-fold change of the control (1). *p < 0.05 vs control; **p < 0.01 vs control; ***p < 0.001 vs control; ****p < 0.0001 vs control. n.s. = not significant, p > 0.05 vs control. N/A = not applicable due to no amplification detected. Gene function was obtained searching the UniProt or NCBI Gene Databases.
removed under vacuum, and extracted with dichloromethane twice and dried over MgSO 4 . The organic layer was concentrated in vacuum and refined by chromatography to give the Compound F and H. Stability Assessment Assay. Each compound was dissolved in 1 mL DMSO and diluted by DMSO to a final concentration of 1 mM/L, then 2 μL solution and 98 μL phosphate buffer (pH 7.4) were mixed in the eppendorf tube. The optical density values from 250 to 600 nm were determined using a Spectrum Max M5 (Molecular Devices, USA). Taking 5 minutes as intervals, the absorption curve was recorded for over 25 minutes. The measured setting was at 25 °C at varying time interval in a 1 cm path-length quartz cuvette. In this experiments, the decline of absorption spectrum at different moments was interpreted as the degradation of compound, which reflects the stability of compound in vitro.
Cell Culture. Table 8 . Summary of the Relative-Fold Change in Gene Expression Utilizing RT 2 PCR. Statistical analysis was performed using One-Way ANOVA to relative-fold change of the control (1). *p < 0.05 vs control; **p < 0.01 vs control; ***p < 0.001 vs control; ****p < 0.0001 vs control. n.s. = not significant, p > 0.05 vs control. N/A= not applicable due to no amplification detected. Gene function was obtained searching the UniProt or NCBI Gene Databases.
The NCI-H23 non-small cell lung cancer cell line (ATCC, Cat. No. CRL-5800, Manassas, VA, USA), was grown and cultured in RPMI-1640 medium (Sigma-Aldrich Canada, Mississauga, ON, Canada) supplemented with 10% (v/v) FBS standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada).
The Apoptotic Detection by Annexing V binding Assay and Propidium Iodide (PI) Staining. Cells were seeded in 6-well plates at 275,000 cells/well if suspension or 100,000 cells/well if adherent and allowed to incubate overnight. Cells were treated with vehicle control (DMSO) or indicated compound for a specified amount of time. Cells were collected and spun down at 3000 rpm, washed in 1xPBS and resuspended in Annexin V binding buffer (10 For qualitative measurement of apoptosis, a similar procedure was carried out with the exception of adherent cells being grown and imaged on 35 mm Glass Bottom Culture Dishes (MatTek Corporation, Cat. No. P35G-0.170-14-C, Ashland, MA, USA) and suspension cells were imaged on a microscope slide with cover slips. Furthermore, cells were counterstained with Hoechst 33258 (Sigma-Aldrich Canada, Cat. No. 861405, Mississauga, ON, Canada) with a final concentration of 10 μM during the 15 minute incubation. All groups were subjected to micrographs that were taken on a Leica DM IRB inverted fluorescence microscope (Leica Microsystems, Wetzlar, Germany) at 20x, or 40x objective lens.
Mitochondrial Membrane Potential Measurement. Tetramethylrhodamine methyl ester (TMRM) was used to monitor mitochondria membrane potential (MMP). Cells were seeded in 6-well plates at 275,000 cells/well if suspension or 100,000 cells/well if adherent and allowed to incubate overnight. Cells were treated with vehicle control (DMSO) or indicated compound for a specified amount of time. Cells were collected and allowed to incubate in TMRM at a final concentration of 100 nM for 45 minutes.
For quantification, cells were collected and washed in 1xPBS before subjected to image-based cytometry using the Tali Whole Cell Detection of Reactive Oxygen Species. 7′-dichlorofluorescin diacetate (DCFDA) was used to detect whole cell ROS. Cells were seeded in 6-well plates at 275,000 cells/well if suspension or 100,000 cells/well if adherent and allowed to incubate overnight. DCFDA was pretreated for 30 minutes at a final concentration of 20 μM at 37 °C then cells were treated with the negative control (DMSO vehicle) or the compounds being studied (dissolved in DMSO or water) for 3 or 6 hours protected from light. For the 24-hour time point, cells were treated first with studied compound or DMSO then treated with DCFDA at the 18-hour time point for 6 hours. Cells were then collected in 2 mL eppendorfs followed by centrifugation at 2000 RPM for 5 minutes. Media was aspirated and resuspended in 1xPBS. Results were quantified using the Tali Image-Based Cytometer (LifeTechnologies Inc, Cat. No. T10796, Burlington, ON, Canada) and were measured as the percent of cells positive for the green fluorescent product, DCF relative to the DMSO control.
Growth Curve Post-Treatment Removal. Cells were plated and treated with their respective doses for a period of time. Cells were then collected and washed in 1xPBS. Each group was re-plated with the same amount of cells with fresh media not containing any treatments and then allowed to recover for 24 or 48 hours. Cells were then collected and the number of healthy cells was counted using trypan blue (Sigma-Aldrich Canada, Cat. No. T8154, Mississauga, ON, Canada). For the E6-1 cell line 100,000 cells were plated to begin the assay, treated for 24 hours and re-plated with 50,000 cells with fresh media for 24 or 48 hours. For the MBA-MD-231 cell line 100,000 cells were plated to begin the assay, treated for 48 hours, then re-plated with 30,000 cells with fresh media for 24, 48, or 72 hours.
Cell Lysis. Cells were plated in 10 cm petri dishes at 2 × 10 6 if suspension or 1.5 or 1 × 10 6 cells/dish if adherent and allowed to incubate overnight. Cells were treated with indicated compounds or DMSO for the designated time point. Cells were then collected and washed once with PBS. Cells were then suspended in ice cold lysis buffer (1% Triton X-100, 50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS and ddH 2 O, pH = 7.3), with HaltTM Protease Inhibitor Cocktail (100X) (ThermoFisher Scientific, Cat. No. 78438, Waltham, MA, USA) using manufactures protocol and incubated on ice for 5 minutes. Using a P1000, slowly pipetting ten times to lyse the cells. Cells were spun down at 10,000 RPM at 4 °C for 10 minutes to separate the cytosolic content and cell debris. Using the Bradford assay, each sample had approximately 30 μg of protein. No. PK-6102]) for 75 minutes. The sections were then incubated in avidin biotin complex (ABC reagent) for 45 minutes at room temperature. Following two additional TBS washes, the sections were subjected to the peroxidase substrate 3, 3′ diaminobenzidine (DAB) prepared as per the instructions in the kit (Vector Laboratories, DAB Peroxidase (HRP) Substrate Kit [Cat. No. SK-4100]). Sections were then counterstained with Hematoxylin Solution, Gill No. 1 (Sigma-Aldrich Canada, Cat. No. GHS116, Mississauga, ON, Canada) and washed twice in tap water and once in 1xTBS for 5 minutes. The sections were then dehydrated in anhydrous ethanol and xylene and were cover-slipped using Permount for visualization under a microscope.
Cytosol-Mitochondria Fraction
Statistics. All statistics were performed by GraphPad Prism 6 statistical software. A p-value below 0.05 was considered significant. Different statistical analysis was performed depending on the variables in each experiment. For the experiments with single variable measurements, which include quantification of mitochondrial membrane potential, and whole cell ROS, One-Way ANOVA (nonparametric) was conducted and each samples' mean was compared to the mean of the negative control (DMSO) unless otherwise specified. For experiments that were multi-variable such as the quantification of early and late apoptosis Two-Way ANOVA (nonparametric) was used and each samples' mean was compared to the mean of the negative control (DMSO) unless otherwise specified.
